News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim GmbH Release: Head-To-Head Study Shows COPD Patients Achieve Significantly Better Lung Function Improvements With The Combination Of Spiriva(R) And Formoterol Than The Combination Of Salmeterol And Fluticasone Propionate


10/19/2005 5:12:17 PM

Copenhagen/Denmark, 19 September 2005 - Patients with Chronic Obstructive Pulmonary Disease (COPD) achieved superior lung function improvements when treated with the free combination of two bronchodilators with different modes-of-action, Spiriva® (tiotropium) and formoterol, compared with the free combination of one bronchodilator, salmeterol, and an anti-inflammatory, fluticasone propionate, according to the results of a study presented today at the annual European Respiratory Society congress. (1)



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES